Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors would like to thank the patients, their relatives and caregivers, and investigators and staff involved in this analysis. C.R. and W.T. receive funding from the NIHR UCLH Biomedical Research Centre. We also acknowledge the massive contribution of Professor A.P. to the CAR-T community in the UK.

Disclosure statement

A.K., S.C. A.P., and C.R. have served on advisory boards and received honoraria from Kite/Gilead, Novartis, and BMS. K.C. and A.A.K. received honoraria from Kite/Gilead. R.S., D.I., B.U., E.T., and M.O. have served on advisory boards and received honoraria from Kite/Gilead and Novartis. T.M has served on advisory boards and received honoraria from Kite/Gilead, Novartis, BMS, Janssen, Roche, Servier, Pfizer, and Amgen. W.T. has received honoraria and consultancy fees from Kite, BMS, and Roche.

K.C., C.R., A.P., R.S., A.A.K. designed the research, collected the data, analyzed the data, and wrote the manuscript; T.M., E.T., S.C., A.M., B.U., J.R., D.I., R.J., E.N., J.B., W.T., A.K., M.O. contributed to collecting the data and writing the manuscript.

Additional information

Funding

This work was supported by the NIHR UCLH Biomedical Research Centre.